An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Name: An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
Published: 2016
License: Public Domain

ViiV Healthcare · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

efficacy hiv-1 hiv-infections human-immunodeficiency-virus infection safety

infection, human immunodeficiency virus, hiv infections, tolerability, hiv 1, efficacy, treatment naïve, two-drug regimen, safety, non inferiority, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Related documents